Therefore, the HDAC1 inhibitor is still risky as a potential treatment for correcting epigenome alterations in SLE patients due to its concomitant effect of augmenting the IFN signature in autoimmune diseases (23). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.